AUROBAC THERAPEUTICS is a biopharmaceutical company founded in 2022 by three highly renowned life sciences innovation companies, Boehringer Ingelheim, Evotec and bioMérieux, to become a global leader in the fight against bacterial infections, Antimicrobial Resistance (AMR) and their consequences in acute hospital settings.
AUROBAC’s R&D strategy addresses these unmet medical needs with patient- and pathogen-targeted programs designed to tackle both the causes and consequences of potentially life-threatening bacterial infections and AMR, including hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP) and sepsis.
Company Details
- Employees
- 34
- Founded
- 2022
- Address
- 29, Avenue Tony Garnier, Lyon,auvergne-Rhône-Alpes 69007,france
- Industry
- Biotechnology
- Website
- https://www.aurobac-tx.com
- Keywords
- IT Consulting.
- HQ
- Lyon, Auvergne-Rhône-Alpes
Aurobac Therapeutics Questions
Aurobac Therapeutics's website is https://www.aurobac-tx.com
Aurobac Therapeutics's LinkedIn profile is https://fr.linkedin.com/company/aurobac-tx
Aurobac Therapeutics has
34 employees.
View email and phone details for 34
employees at Aurobac Therapeutics.
Aurobac Therapeutics's industry is
Biotechnology
Aurobac Therapeutics's top competitors are
Antabio,
Generare,
Pulselife,
Fabentech,
Da Volterra,
Phaxiam Therapeutics,
Osivax,
Amal Therapeutics,
Lyonbiopôle Auvergne-Rhône-Alpes,
Boehringer Ingelheim.
Aurobac Therapeutics's categories are Biotechnology
Aurobac Therapeutics's founding year is 2022
